Biodelivery Sciences International (BDSI) 17.40 $BDSI
BioDelivery Sciences to Develop a Long-Acting Injectable Depot Formulation of Buprenorphine with Evonik for Use in Opioid Dependence and Pain
PR Newswire - Tue Oct 28, 7:00AM CDT
BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI) has entered into an exclusive agreement with Evonik Corporation to develop and commercialize a proprietary, injectable microparticle formulation of buprenorphine potentially capable of providing 30 days of continuous therapy following a single subcutaneous injection.
BDSI: 17.40 (-0.39)
Surprising Stocks That Performed Best for Billionaires in 2014
at The Street - Mon Oct 27, 7:48AM CDT
See the stocks that have performed the best for 19 billionaires who made their money investing.
BDSI: 17.40 (-0.39), ATHL: 58.30 (+0.11), VIPS: 229.29 (+9.40), ARII: 65.81 (-0.15), SBAC: 112.33 (-2.07), BIOF: 7.28 (+0.01), BKW: 32.68 (+0.64), LUV: 34.48 (+0.35), HCA: 70.05 (+0.65), LPDX: 5.22 (+0.01), DTV: 86.79 (+1.41), RCPT: 103.65 (+1.93), WMB: 55.51 (+0.51), BRK.B: 140.16 (+0.62), BRK.A: 210,000.00 (+969.41), SBGL: 7.35 (-0.46), AN: 57.26 (+1.36)
'Mad Money' Lightning Round: You're in Great Shape With Southern
at The Street - Sat Oct 25, 5:00AM CDT
Cramer says NewLink Genetics is too expensive, Home Loan Servicing is too risky but Plains All American Pipeline is terrific.
BDSI: 17.40 (-0.39), SO: 46.36 (-0.09), PAA: 56.35 (+0.38), HLSS: 19.21 (+0.36)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Oct 24, 6:54PM CDT
Earnings will take center stage and Cramer will be watching Merck, Twitter and Facebook, among many others.
BDSI: 17.40 (-0.39), GPRO: 77.10 (+8.85), MCK: 203.41 (-0.07), AXP: 89.95 (+1.21), PNRA: 161.64 (-0.71), FB: 74.99 (+0.88), DECK: 87.46 (-0.33), XOM: 96.71 (+2.26), BWLD: 149.28 (-0.76), SO: 46.36 (-0.09), PANW: 105.70 (+0.77), PAA: 56.35 (+0.38), WLP: 126.69 (+3.40), SBUX: 75.56 (-1.76), PH: 127.03 (+2.36), GILD: 112.00 (-2.22), MRK: 57.94 (+0.63), DD: 69.15 (+1.49), PAY: 37.26 (+0.58), TWTR: 41.47 (-0.33), CVX: 119.95 (+2.75), AAPL: 108.00 (+1.02), HLSS: 19.21 (+0.36)
BioDelivery Sciences elects J Chris Prue as VP of Regulatory Affairs and Quality Assurance
M2 - Mon Oct 13, 5:53AM CDT
Pharmaceutical company BioDelivery Sciences International (NasdaqCM:BDSI) disclosed on Friday the election of J Chris Prue, RPh, MBA as vice president of its Regulatory Affairs and Quality Assurance.
BDSI: 17.40 (-0.39)
BioDelivery Sciences Announces the Hiring of J. Chris Prue as Vice President of Regulatory Affairs and Quality Assurance
PR Newswire - Fri Oct 10, 10:15AM CDT
BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI) announced that J. Chris Prue, RPh, MBA has joined BDSI as Vice President of Regulatory Affairs and Quality Assurance.
BDSI: 17.40 (-0.39)
Shares of BDSI Up 93.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Oct 10, 9:23AM CDT
SmarTrend identified an Uptrend for BioDelivery Sciences (NASDAQ:BDSI) on April 24th, 2014 at $8.61. In approximately 6 months, BioDelivery Sciences has returned 93.03% as of today's recent price of $16.61.
BDSI: 17.40 (-0.39)
Downgrade Alert for BioDelivery Sciences (BDSI)
Comtex SmarTrend(R) - Fri Oct 10, 6:57AM CDT
BioDelivery Sciences (NASDAQ:BDSI) was downgraded from Buy to Neutral at Roth Capital today. The stock closed yesterday at $17.03 on volume of 1.1 million shares, below average daily volume of 1.5 million. BioDelivery Sciences share prices have moved between a 52-week high of $18.48 and a 52-week low of $4.16 and closed yesterday at 309% above that low price at $17.03 per share. Over the last five market days, the 200-day moving average (MA) has gone up 1.7% while the 50-day MA has advanced 1.8%.
BDSI: 17.40 (-0.39)
BioDelivery Sciences Surpasses +200% YTD Gain
at The Street - Tue Oct 07, 12:23PM CDT
21Vianet Group (NASDAQ:VNET), Petroleo Brasileiro Petrobras SA (NYSE
BR) and BioDelivery Sciences International Inc. (NASDAQ:BDSI) got a strong start to the day this Tuesday. In the red midday are En...
VNET: 20.92 (+1.09), BDSI: 17.40 (-0.39), PBR: 11.70 (+0.38), DLIA: 0.11 (-0.01), END: 0.16 (-0.03)
BioDelivery Sciences to Provide BUNAVAIL Launch Update
PR Newswire - Mon Oct 06, 6:49PM CDT
BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI) will host an investor update conference call and webcast to discuss the launch of BUNAVAIL(TM) (buprenorphine and naloxone) buccal film (CIII) which has been approved by the U.S. Food and Drug Administration (FDA) for the maintenance treatment of opioid dependence. The conference call and webcast will take place on Tuesday, October 7 at 8:00 AM Eastern Time.
BDSI: 17.40 (-0.39)
US Patent Office Institutes Inter Partes Review Brought by MonoSol Rx Against All Claims in Key BDSI BEMA Patent
GlobeNewswire - Mon Oct 06, 8:35AM CDT
The United States Patent and Trademark Office (USPTO) has granted MonoSol Rx, LLC's (MonoSol Rx) petition for inter partes review (IPR) of all claims of US Patent No. 7,579,019 ("the '019 patent"
and has instituted the IPR. The '019 patent, owned by Arius Two, Inc, a wholly-owned subsidiary of BioDelivery Sciences International, Inc. (Nasdaq:BDSI) ("BDSI" , is cited by BDSI as a key patent in their BEMA drug delivery technology. Based on information provided by MonoSol Rx in its IPR petition, the USPTO's decision to institute the post-grant USPTO trial was based on the USPTO's agreement that MonoSol Rx established a reasonable likelihood that all of the claims in the '019 patent are invalid. The trial is now proceeding, with a final decision by the USPTO on whether any claims will survive expected by August 2015. Among the reasons for instituting the IPR are grounds of anticipation. Anticipation grounds are particularly powerful because they indicate that the invention lacks novelty, the very thing that BDSI touts as its strength in the BEMA technology. The USPTO's institution of the IPR proceeding against all of the claims of the '019 patent is also a significant development because the '019 Patent is listed in the United States Food and Drug Administration's "Orange Book" as a patent that specifically covers technology used in BDSI's BUNAVAIL product.
BDSI: 17.40 (-0.39)
Actavis in Patent Infringement Lawsuit for Purdue's Butrans - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 01, 4:20PM CDT
Actavis plc (ACT) is looking to bring its generic version of Purdue Pharma's Butrans to the market.
MNK: 92.18 (-0.65), BDSI: 17.40 (-0.39), ACT: 242.74 (-0.47), PFE: 29.95 (+0.11)
96.8% Return Seen to Date on SmarTrend BioDelivery Sciences Call (BDSI)
Comtex SmarTrend(R) - Wed Oct 01, 9:09AM CDT
SmarTrend identified an Uptrend for BioDelivery Sciences (NASDAQ:BDSI) on April 24th, 2014 at $8.61. In approximately 5 months, BioDelivery Sciences has returned 96.80% as of today's recent price of $16.93.
BDSI: 17.40 (-0.39)
Active Equities to Watch in Pharma Industry - Pfizer, BioDelivery Sciences Intl., Repros Therapeutics, Catalent, and Nektar Therapeutics
PR Newswire - Wed Sep 24, 7:30AM CDT
On Tuesday, September 23, 2014, the NASDAQ Composite ended at 4,508.69, down 0.42%, the Dow Jones Industrial Average finished the day 0.68% lower at 17,055.87, and the S&P 500 closed at 1,982.77, down 0.58%. The losses were broad based as all the ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 742.96, down 0.58%, while the index has advanced 2.15% in the last one month. Investor-Edge has initiated coverage on the following equities: Pfizer Inc. (NYSE: PFE), BioDelivery Sciences International Inc. (NASDAQ: BDSI), Repros Therapeutics Inc. (NASDAQ: RPRX), Catalent Inc. (NYSE: CTLT), and Nektar Therapeutics (NASDAQ: NKTR). Free research on these five companies can be accessed at:
BDSI: 17.40 (-0.39), CTLT: 26.03 (+0.39), PFE: 29.95 (+0.11), RPRX: 6.34 (-0.41), NKTR: 13.79 (-0.24)
Uptrend Call Working As BioDelivery Sciences Stock Rises 92.2% (BDSI)
Comtex SmarTrend(R) - Mon Sep 22, 9:06AM CDT
SmarTrend identified an Uptrend for BioDelivery Sciences (NASDAQ:BDSI) on April 24th, 2014 at $8.61. In approximately 5 months, BioDelivery Sciences has returned 92.21% as of today's recent price of $16.54.
BDSI: 17.40 (-0.39)
3 Biotech Breakout Charts That Could See More Upside
at The Street - Thu Sep 11, 12:47PM CDT
Strong charts continue to be found in this uncertain market, especially in the biotechs. Here are four to watch for more upside.
BDSI: 17.40 (-0.39), CMRX: 31.04 (+1.15), ARWR: 6.52 (-0.21)
103.0% Return Seen to Date on SmarTrend BioDelivery Sciences Call (BDSI)
Comtex SmarTrend(R) - Wed Sep 10, 10:56AM CDT
SmarTrend identified an Uptrend for BioDelivery Sciences (NASDAQ:BDSI) on April 24th, 2014 at $8.61. In approximately 5 months, BioDelivery Sciences has returned 103.02% as of today's recent price of $17.47.
BDSI: 17.40 (-0.39)
Insider Trading Alert - MWIV, BDSI And VRTS Traded By Insiders
at The Street - Mon Sep 08, 10:30AM CDT
Stocks with insider trader activity include MWIV, BDSI and VRTS
BDSI: 17.40 (-0.39), MWIV: 169.65 (+3.85), VRTS: 179.21 (-1.54)
BioDelivery Sciences (BDSI) Jumps: Stock Rises 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 7:51AM CDT
BioDelivery Sciences International, Inc. (BDSI) was a big mover last session, as its shares rose almost 9% on the day.
CBPO: 60.25 (+0.60), BDSI: 17.40 (-0.39), CBM: 21.08 (+0.22), GILD: 112.00 (-2.22)
BioDelivery Sciences to Present at the Morgan Stanley Global Healthcare Conference
PR Newswire - Mon Sep 08, 6:00AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at the Morgan Stanley Global Healthcare Conference. The presentation is scheduled for Tuesday, September 9, 2014 at 4:40 p.m. Eastern Time at the Grand Hyatt in New York City.
BDSI: 17.40 (-0.39), MS: 34.95 (+0.43)
BioDelivery Sciences to Develop a Long-Acting Injectable Depot Formulation of Buprenorphine with Evonik for Use in Opioid Dependence and Pain
PR Newswire - Tue Oct 28, 7:00AM CDT
BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI) has entered into an exclusive agreement with Evonik Corporation to develop and commercialize a proprietary, injectable microparticle formulation of buprenorphine potentially capable of providing 30 days of continuous therapy following a single subcutaneous injection.
BDSI: 17.40 (-0.39)
Surprising Stocks That Performed Best for Billionaires in 2014
at The Street - Mon Oct 27, 7:48AM CDT
See the stocks that have performed the best for 19 billionaires who made their money investing.
BDSI: 17.40 (-0.39), ATHL: 58.30 (+0.11), VIPS: 229.29 (+9.40), ARII: 65.81 (-0.15), SBAC: 112.33 (-2.07), BIOF: 7.28 (+0.01), BKW: 32.68 (+0.64), LUV: 34.48 (+0.35), HCA: 70.05 (+0.65), LPDX: 5.22 (+0.01), DTV: 86.79 (+1.41), RCPT: 103.65 (+1.93), WMB: 55.51 (+0.51), BRK.B: 140.16 (+0.62), BRK.A: 210,000.00 (+969.41), SBGL: 7.35 (-0.46), AN: 57.26 (+1.36)
'Mad Money' Lightning Round: You're in Great Shape With Southern
at The Street - Sat Oct 25, 5:00AM CDT
Cramer says NewLink Genetics is too expensive, Home Loan Servicing is too risky but Plains All American Pipeline is terrific.
BDSI: 17.40 (-0.39), SO: 46.36 (-0.09), PAA: 56.35 (+0.38), HLSS: 19.21 (+0.36)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Oct 24, 6:54PM CDT
Earnings will take center stage and Cramer will be watching Merck, Twitter and Facebook, among many others.
BDSI: 17.40 (-0.39), GPRO: 77.10 (+8.85), MCK: 203.41 (-0.07), AXP: 89.95 (+1.21), PNRA: 161.64 (-0.71), FB: 74.99 (+0.88), DECK: 87.46 (-0.33), XOM: 96.71 (+2.26), BWLD: 149.28 (-0.76), SO: 46.36 (-0.09), PANW: 105.70 (+0.77), PAA: 56.35 (+0.38), WLP: 126.69 (+3.40), SBUX: 75.56 (-1.76), PH: 127.03 (+2.36), GILD: 112.00 (-2.22), MRK: 57.94 (+0.63), DD: 69.15 (+1.49), PAY: 37.26 (+0.58), TWTR: 41.47 (-0.33), CVX: 119.95 (+2.75), AAPL: 108.00 (+1.02), HLSS: 19.21 (+0.36)
BioDelivery Sciences elects J Chris Prue as VP of Regulatory Affairs and Quality Assurance
M2 - Mon Oct 13, 5:53AM CDT
Pharmaceutical company BioDelivery Sciences International (NasdaqCM:BDSI) disclosed on Friday the election of J Chris Prue, RPh, MBA as vice president of its Regulatory Affairs and Quality Assurance.
BDSI: 17.40 (-0.39)
BioDelivery Sciences Announces the Hiring of J. Chris Prue as Vice President of Regulatory Affairs and Quality Assurance
PR Newswire - Fri Oct 10, 10:15AM CDT
BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI) announced that J. Chris Prue, RPh, MBA has joined BDSI as Vice President of Regulatory Affairs and Quality Assurance.
BDSI: 17.40 (-0.39)
Shares of BDSI Up 93.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Oct 10, 9:23AM CDT
SmarTrend identified an Uptrend for BioDelivery Sciences (NASDAQ:BDSI) on April 24th, 2014 at $8.61. In approximately 6 months, BioDelivery Sciences has returned 93.03% as of today's recent price of $16.61.
BDSI: 17.40 (-0.39)
Downgrade Alert for BioDelivery Sciences (BDSI)
Comtex SmarTrend(R) - Fri Oct 10, 6:57AM CDT
BioDelivery Sciences (NASDAQ:BDSI) was downgraded from Buy to Neutral at Roth Capital today. The stock closed yesterday at $17.03 on volume of 1.1 million shares, below average daily volume of 1.5 million. BioDelivery Sciences share prices have moved between a 52-week high of $18.48 and a 52-week low of $4.16 and closed yesterday at 309% above that low price at $17.03 per share. Over the last five market days, the 200-day moving average (MA) has gone up 1.7% while the 50-day MA has advanced 1.8%.
BDSI: 17.40 (-0.39)
BioDelivery Sciences Surpasses +200% YTD Gain
at The Street - Tue Oct 07, 12:23PM CDT
21Vianet Group (NASDAQ:VNET), Petroleo Brasileiro Petrobras SA (NYSE
BR) and BioDelivery Sciences International Inc. (NASDAQ:BDSI) got a strong start to the day this Tuesday. In the red midday are En... VNET: 20.92 (+1.09), BDSI: 17.40 (-0.39), PBR: 11.70 (+0.38), DLIA: 0.11 (-0.01), END: 0.16 (-0.03)
BioDelivery Sciences to Provide BUNAVAIL Launch Update
PR Newswire - Mon Oct 06, 6:49PM CDT
BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI) will host an investor update conference call and webcast to discuss the launch of BUNAVAIL(TM) (buprenorphine and naloxone) buccal film (CIII) which has been approved by the U.S. Food and Drug Administration (FDA) for the maintenance treatment of opioid dependence. The conference call and webcast will take place on Tuesday, October 7 at 8:00 AM Eastern Time.
BDSI: 17.40 (-0.39)
US Patent Office Institutes Inter Partes Review Brought by MonoSol Rx Against All Claims in Key BDSI BEMA Patent
GlobeNewswire - Mon Oct 06, 8:35AM CDT
The United States Patent and Trademark Office (USPTO) has granted MonoSol Rx, LLC's (MonoSol Rx) petition for inter partes review (IPR) of all claims of US Patent No. 7,579,019 ("the '019 patent"
and has instituted the IPR. The '019 patent, owned by Arius Two, Inc, a wholly-owned subsidiary of BioDelivery Sciences International, Inc. (Nasdaq:BDSI) ("BDSI" , is cited by BDSI as a key patent in their BEMA drug delivery technology. Based on information provided by MonoSol Rx in its IPR petition, the USPTO's decision to institute the post-grant USPTO trial was based on the USPTO's agreement that MonoSol Rx established a reasonable likelihood that all of the claims in the '019 patent are invalid. The trial is now proceeding, with a final decision by the USPTO on whether any claims will survive expected by August 2015. Among the reasons for instituting the IPR are grounds of anticipation. Anticipation grounds are particularly powerful because they indicate that the invention lacks novelty, the very thing that BDSI touts as its strength in the BEMA technology. The USPTO's institution of the IPR proceeding against all of the claims of the '019 patent is also a significant development because the '019 Patent is listed in the United States Food and Drug Administration's "Orange Book" as a patent that specifically covers technology used in BDSI's BUNAVAIL product. BDSI: 17.40 (-0.39)
Actavis in Patent Infringement Lawsuit for Purdue's Butrans - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 01, 4:20PM CDT
Actavis plc (ACT) is looking to bring its generic version of Purdue Pharma's Butrans to the market.
MNK: 92.18 (-0.65), BDSI: 17.40 (-0.39), ACT: 242.74 (-0.47), PFE: 29.95 (+0.11)
96.8% Return Seen to Date on SmarTrend BioDelivery Sciences Call (BDSI)
Comtex SmarTrend(R) - Wed Oct 01, 9:09AM CDT
SmarTrend identified an Uptrend for BioDelivery Sciences (NASDAQ:BDSI) on April 24th, 2014 at $8.61. In approximately 5 months, BioDelivery Sciences has returned 96.80% as of today's recent price of $16.93.
BDSI: 17.40 (-0.39)
Active Equities to Watch in Pharma Industry - Pfizer, BioDelivery Sciences Intl., Repros Therapeutics, Catalent, and Nektar Therapeutics
PR Newswire - Wed Sep 24, 7:30AM CDT
On Tuesday, September 23, 2014, the NASDAQ Composite ended at 4,508.69, down 0.42%, the Dow Jones Industrial Average finished the day 0.68% lower at 17,055.87, and the S&P 500 closed at 1,982.77, down 0.58%. The losses were broad based as all the ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 742.96, down 0.58%, while the index has advanced 2.15% in the last one month. Investor-Edge has initiated coverage on the following equities: Pfizer Inc. (NYSE: PFE), BioDelivery Sciences International Inc. (NASDAQ: BDSI), Repros Therapeutics Inc. (NASDAQ: RPRX), Catalent Inc. (NYSE: CTLT), and Nektar Therapeutics (NASDAQ: NKTR). Free research on these five companies can be accessed at:
BDSI: 17.40 (-0.39), CTLT: 26.03 (+0.39), PFE: 29.95 (+0.11), RPRX: 6.34 (-0.41), NKTR: 13.79 (-0.24)
Uptrend Call Working As BioDelivery Sciences Stock Rises 92.2% (BDSI)
Comtex SmarTrend(R) - Mon Sep 22, 9:06AM CDT
SmarTrend identified an Uptrend for BioDelivery Sciences (NASDAQ:BDSI) on April 24th, 2014 at $8.61. In approximately 5 months, BioDelivery Sciences has returned 92.21% as of today's recent price of $16.54.
BDSI: 17.40 (-0.39)
3 Biotech Breakout Charts That Could See More Upside
at The Street - Thu Sep 11, 12:47PM CDT
Strong charts continue to be found in this uncertain market, especially in the biotechs. Here are four to watch for more upside.
BDSI: 17.40 (-0.39), CMRX: 31.04 (+1.15), ARWR: 6.52 (-0.21)
103.0% Return Seen to Date on SmarTrend BioDelivery Sciences Call (BDSI)
Comtex SmarTrend(R) - Wed Sep 10, 10:56AM CDT
SmarTrend identified an Uptrend for BioDelivery Sciences (NASDAQ:BDSI) on April 24th, 2014 at $8.61. In approximately 5 months, BioDelivery Sciences has returned 103.02% as of today's recent price of $17.47.
BDSI: 17.40 (-0.39)
Insider Trading Alert - MWIV, BDSI And VRTS Traded By Insiders
at The Street - Mon Sep 08, 10:30AM CDT
Stocks with insider trader activity include MWIV, BDSI and VRTS
BDSI: 17.40 (-0.39), MWIV: 169.65 (+3.85), VRTS: 179.21 (-1.54)
BioDelivery Sciences (BDSI) Jumps: Stock Rises 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 7:51AM CDT
BioDelivery Sciences International, Inc. (BDSI) was a big mover last session, as its shares rose almost 9% on the day.
CBPO: 60.25 (+0.60), BDSI: 17.40 (-0.39), CBM: 21.08 (+0.22), GILD: 112.00 (-2.22)
BioDelivery Sciences to Present at the Morgan Stanley Global Healthcare Conference
PR Newswire - Mon Sep 08, 6:00AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at the Morgan Stanley Global Healthcare Conference. The presentation is scheduled for Tuesday, September 9, 2014 at 4:40 p.m. Eastern Time at the Grand Hyatt in New York City.
BDSI: 17.40 (-0.39), MS: 34.95 (+0.43)
